Literature DB >> 8643110

Production and characterization of bispecific single-chain antibody fragments.

J De Jonge1, J Brissinck, C Heirman, C Demanet, O Leo, M Moser, K Thielemans.   

Abstract

We report the construction, expression and purification of a bispecific single-chain Fv antibody fragment produced in Escherichia coli. The protein possesses a dual specificity: the single-chain FvB1 portion is directed to the Idiotype of BCL1 lymphoma cells, the single-chain Fv2C11 moiety binds to the CD3 marker on T cells. The two domains are joined by a flexible peptide linker. Using Immobilized Metal Affinity Chromatography, the recombinant protein was purified from bacterial insoluble membrane fractions. After refolding of the bispecific protein, it was affinity-purified. As demonstrated by flow cytometry, both binding sites are retained in the refolded protein. Retargeted cytotoxicity and T cell proliferation assays further prove the biological activity and specificity of the bispecific single-chain Fv. Thus, these bispecific molecules show a potential anti-tumor activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8643110     DOI: 10.1016/0161-5890(95)00089-5

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

1.  Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody.

Authors:  Ryutaro Asano; Keiko Ikoma; Ippei Shimomura; Shintaro Taki; Takeshi Nakanishi; Mitsuo Umetsu; Izumi Kumagai
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

Review 2.  Are BiTEs the "missing link" in cancer therapy?

Authors:  Carter M Suryadevara; Patrick C Gedeon; Luis Sanchez-Perez; Terence Verla; Christopher Alvarez-Breckenridge; Bryan D Choi; Peter E Fecci; John H Sampson
Journal:  Oncoimmunology       Date:  2015-04-30       Impact factor: 8.110

3.  Engineering tandem single-chain Fv as cell surface reporters with enhanced properties of fluorescence detection.

Authors:  Eugenio Gallo; Avin C Snyder; Jonathan W Jarvik
Journal:  Protein Eng Des Sel       Date:  2015-04-05       Impact factor: 1.650

Review 4.  An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.

Authors:  Patrick C Gedeon; Bryan D Choi; Tiffany R Hodges; Duane A Mitchell; Darell D Bigner; John H Sampson
Journal:  Expert Rev Clin Pharmacol       Date:  2013-07       Impact factor: 5.045

Review 5.  The making of bispecific antibodies.

Authors:  Ulrich Brinkmann; Roland E Kontermann
Journal:  MAbs       Date:  2017 Feb/Mar       Impact factor: 5.857

6.  Glutaraldehyde-Modified Recombinant Fel d 1: A Hypoallergen With Negligible Biological Activity But Retained Immunogenicity.

Authors:  Serge A Versteeg; Ingrid Bulder; Martin Himly; Toni M van Capel; R van den Hout; Stef J Koppelman; Esther C de Jong; Fatima Ferreira; Ronald van Ree
Journal:  World Allergy Organ J       Date:  2011-07-14       Impact factor: 4.084

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.